Spinal Muscular Atrophy: Entering the Treatment Age

AbstractPurpose of ReviewSpinal muscular atrophy is a devastating neurodegenerative disorder. With the recent approval of the first treatment, nusinersen (Spinraza), the natural course of the disease will change. It poses new challenges in administration and highlights the importance of early diagnosis.Recent FindingsNusinersen, an antisense oligonucleotide, helps to ameliorate disease severity in patients with spinal muscular atrophy (SMA)1 and SMA2 early in their disease course, helping to decrease the risk of death and respiratory support, as well as enhance motor outcomes in all patients with SMA. Treatment earlier in the course of disease is associated with better outcomes. Overall, treatment is well tolerated, but repeated intrathecal administration can be both technically difficult as well as expensive.SummaryNusinersen is an important step forward in the treatment of spinal muscular atrophy. With the availability of a treatment, we have to change our approach to diagnosis, focusing on carrier testing and/or newborn screening as well as a low threshold for clinical testing.
Source: Current Pediatrics Reports - Category: Pediatrics Source Type: research